NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

171.68
-1.46
(-0.84%)
As of 10:47:30 AM EDT. Market Open.
Loading Chart for BDX
  • Previous Close 173.14
  • Open 171.03
  • Bid 171.65 x 4000
  • Ask 171.79 x 800
  • Day's Range 170.82 - 172.26
  • 52 Week Range 163.33 - 251.99
  • Volume 371,657
  • Avg. Volume 2,810,883
  • Market Cap (intraday) 49.206B
  • Beta (5Y Monthly) 0.34
  • PE Ratio (TTM) 33.27
  • EPS (TTM) 5.16
  • Earnings Date Aug 7, 2025
  • Forward Dividend & Yield 4.16 (2.40%)
  • Ex-Dividend Date Jun 9, 2025
  • 1y Target Est 225.25

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

70,000

Full Time Employees

September 30

Fiscal Year Ends

Recent News: BDX

View More

Performance Overview: BDX

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BDX
23.98%
S&P 500 (^GSPC)
0.73%

1-Year Return

BDX
25.49%
S&P 500 (^GSPC)
10.02%

3-Year Return

BDX
28.69%
S&P 500 (^GSPC)
49.65%

5-Year Return

BDX
20.81%
S&P 500 (^GSPC)
97.55%

Compare To: BDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDX

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    49.62B

  • Enterprise Value

    68.21B

  • Trailing P/E

    33.55

  • Forward P/E

    12.45

  • PEG Ratio (5yr expected)

    0.80

  • Price/Sales (ttm)

    2.41

  • Price/Book (mrq)

    1.97

  • Enterprise Value/Revenue

    3.27

  • Enterprise Value/EBITDA

    14.67

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.18%

  • Return on Assets (ttm)

    3.69%

  • Return on Equity (ttm)

    5.89%

  • Revenue (ttm)

    20.87B

  • Net Income Avi to Common (ttm)

    1.5B

  • Diluted EPS (ttm)

    5.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    683M

  • Total Debt/Equity (mrq)

    76.34%

  • Levered Free Cash Flow (ttm)

    3.5B

Research Analysis: BDX

View More

Company Insights: BDX

Research Reports: BDX

View More

People Also Watch